AbstractText: Performing limb salvage with safe margins and preserving meaningful function is very difficult in the setting of primary malignantbone and softtissuetumors due to the complex and constrained anatomy of the foot and ankle... The functional outcomes were assessed with MusculoskeletalTumor Society (MSTS) scores. Limb survival and oncological outcomes were evaluated according to Kaplan-Meier curves ...
... many years, first-line treatment for locally advanced or metastatic soft-tissuesarcoma has been doxorubicin... versus doxorubicin as first-line treatment for advanced or metastatic soft-tissuesarcoma AbstractText: The GeDDiS trial was a randomised controlled phase 3 ... when selecting first-line treatment for locally advanced or metastatic soft-tissuesarcoma AbstractText: Cancer Research UK, Sarcoma UK, and Clinical Trial Unit Kantonsspital St Gallen ...
Oncology (3) Sarcoma (8), Neutropenia (4), Neoplasms (3), more mentions
The mean MusculoskeletalTumor Society (MSTS) scores were as follows: osteochondral graft 70%; intercalary graft 73%; inlay graft 89%; and resection arthrodesis 83% AbstractText: Although associated with a relatively high rate of complications ... Cite this article: Bone Joint J 2017;99-B:1237-43 Keyword: Bone and soft-tissuetumour.
Imaging studies were reviewed to assess tumour extension and soft-tissue involvement... a deltoid sparing procedure if they presented with a small tumour (p = 0.0064) with less bone involvement (p = 0.032) and a continuous fat rim on MRI ... control after resection of the proximal humerus for a primary malignantbonetumour.
Postoperative complications (POCs) negatively impact oncologic outcomes in some malignancies; however, little is known regarding their effect in softtissuesarcoma (STS. The aim of this study was to determine the impact of POCs on survival after resection of truncal and extremity STS.All patients who underwent resection for a primary truncal or extremity STS at a single academic institution ...
Oncology (1) Neoplasms (2), Sarcoma (2), Infections (1), more mentions
This study aimed to quantify the benefit of adjuvant radiotherapy (AXRT) for local control, distant metastasis, and long-term survival outcomes in patients with localized softtissuesarcoma (STS).This single-center retrospective observational study enrolled 433 STS patients who underwent surgery with curative intent. An inverse probability of treatment-weighted (IPTW) analysis was implemented to account rigorously for imbalances ...
... to prioritize research questions within the field so that the MusculoskeletalTumor Society (MSTS), and other relevant professional societies, can direct the ... stakeholders involved believe will have the most meaningful impact on orthopaediconcology patient care AbstractText: The purpose of this study was to ... priority research questions for future international prospective clinical studies in orthopaediconcology AbstractText: A three-step modified Delphi process involving multiple stakeholder ...
Oncology (7), Muscular and Skeletal Diseases (1) Fibroma (1), Bone Diseases (1), Neoplasms (1), more mentions
The risk of mortality was increased for the majority of cancer types among patients with bone and synchronous metastases compared with bone only (adjusted relative risk 1.29-1.57), except for cervix, ovarian and bladder cancer.While patients with bone metastases after most primary cancers have poor survival, one of ten patients with bonemetastasis from breast cancer survived 5 years ...
Oncology (17) Neoplasms (5), Breast Neoplasms (3), Lung Neoplasms (1), more mentions
Abstract: For decades, doxorubicin alone or in combination with ifosfamide has been used in advanced softtissuesarcoma (STS... We discuss these issues aiming to contribute to the ongoing debate about the optimal approach to perform clinical research in STS Keyword: Advanced softtissuesarcoma. Keyword: Evofosfamide. Keyword: Fosfamides. Keyword: Ifosfamide.
... of this study was to evaluate the role of preoperative and postoperative external beam radiation therapy (EBRT) in the treatment of resectable softtissuesarcomas (STSs) of different tumor locations.A systematic literature search was performed to identify studies investigating the effects of EBRT (versus no EBRT) on local recurrence (LR ...
We present an exceptional case of a patient with high-grade serous ovarian cancer, treated with multiple chemotherapy regimens, who exhibited regression of some metastatic lesions with concomitant progression of other lesions during a treatment-free period. Using immunogenomic approaches, we found that progressing metastases were characterized by immune cell exclusion, whereas regressing and stable metastases were infiltrated by CD8(+) and CD4(+) T cells and exhibited oligoclonal expansion of specific T cell subsets. We also detected CD8(+) T cell reactivity against predicted neoepitopes after isolation of cells from a blood sample taken almost 3 years after the tumors were resected. These findings suggest that multiple distinct tumor immune microenvironments co-exist within a single individual and may explain in part the heterogeneous fates of metastatic lesions often observed in the clinic post-therapy. VIDEO ABSTRACT.
... to the change in bone density, the group with decreased bone density had a shorter distant metastasis-free survival time (DMFS) after surgery than the other group ... Multivariate analysis indicated three significant factors associated with distant metastasis: a decrease in bone density (hazard ratio [HR], 2.17; p = 0.04), normalization of the ...
... MRgFUS) is an alternative local therapy for patients with painful bonemetastasis for whom standard conventional radiation therapy (RT) has failed... therapeutic effects of MRgFUS as a first-line treatment for bonemetastasis remain uncertain.A matched-pair study was conducted to compare ... RT as a first-line treatment for patients with painful bonemetastasis.
PURPOSE: The purpose of this study is to assess the efficacy of (153)Sm-EDTMP (Quadramet®) in a clinical setting.
METHODS: We have conducted a retrospective study of all consecutive patients (pts) treated with (153)Sm-EDTMP for painful bone metastases. At each visit (before and after treatment), four parameters were collected: (i) pain assessment according to the 10-step visual analogue scale (VAS), (ii) sleep disturbance related to pain, (iii) dose of analgesic medication, and (iv) answer to the following closed question "Do you think you obtained a benefit from treatment?" Success of treatment was defined by the combination of these four parameters.
RESULTS: Three hundred seventy consecutive (153)Sm-EDTMP treatments for painful bone metastases were given. Patients had the following primary tumors: breast carcinoma (153), prostate carcinoma (155), lung carcinoma (27), or other cancers (35). Fifty-eight percent of the patients had received previous external osseous radiotherapy. Ninety-seven percent of the patients were treated with concomitant analgesics and 61% were treated with diphosphonates. A clinical benefit was described in 55.0% of cases at D30. Treatment was more effective in cases of breast and prostate cancers compared with other types of primary cancers. Patients described a benefit at D30 in 62, 58, 6, and 38% of cases of breast, prostate, lung, and other cancers. The subjective efficacy was accompanied by a decrease in analgesic intake in 35.0% of cases.
CONCLUSION: (153)Sm-EDTMP therapy is an effective supportive treatment in patients who suffer from bone metastases, especially in patients with breast or prostate cancer.
BACKGROUND: Hepatocellular carcinoma (HCC) represents one of the most common causes of cancer-related deaths worldwide, with rising incidence in the USA. Bone metastases with HCC, in particular, have an extremely poor prognosis. We present prevalence, treatment, and survival of patients with bone and more specifically spinal metastases from HCC.
METHODS: A retrospective analysis was done at a single tertiary care institution of patients with bone metastases from HCC between January 2005 and December 2015.
RESULTS: Among 1017 patients with HCC, 20 were found to have bone metastases of which 11 had spinal metastases. Seventeen (85%) were male, with median age of 58 years at time of HCC diagnosis. Systemic chemotherapy and sorafenib were used in 12 (60%) patients, and 12 (60%) received radiation therapy. Among patients who did not receive therapy, median survival was 76 days. Median survival after diagnosis of metastasis in patients on sorafenib and radiation were 106 and 100 days, respectively.
CONCLUSION: Bone metastases in HCC are very rare and aggressive. Due to its rarity, optimal treatment strategies are not well defined. Early diagnosis is important for optimal therapy and improved survival.
AbstractText: To review the presenting features, treatment, and outcomes for patients with basal cell carcinoma (BCC) involving the temporal bone or external auditory canal (EAC) AbstractText: Retrospective case series AbstractText: Presenting characteristics, treatment strategies, and outcomes ... BCC may be associated with better prognosis than other temporal bonemalignancies AbstractText: 4.
Basal Cell Carcinoma (3), Hearing Loss (1), Neoplasms (1), more mentions
OBJECTIVES: To identify an objective and reproducible strategy for preoperative staging bone scintigraphy [BS] in patients diagnosed with renal cell carcinoma [RCC], since in absence of objective criteria, the decision to perform preoperative BS remains a subjective practice.
METHODS: 2,008 RCC patients treated with surgery and prospectively included into an institutional database. The study outcome was presence of one or more bone lesions suspicious for metastases at staging BS. Multivariable logistic regression model predicting positive BS was fitted. Predictors consisted of preoperative clinical tumour [cT] and nodal [cN] stage, presence of systemic symptoms and platelets/haemoglobin [PLT/Hb] ratio.
RESULTS: The rate of positive BS was 4% (n=81). At multivariable logistic regression analysis, cT2, cN1, presence of systemic symptoms and PLT/Hb ratio were all associated with increased risk of positive BS (p<0.05). Following 2000-sample bootstrap validation, concordance index resulted 0.77 (proposed model) vs. 0.63 (decision-making based on symptoms only). At decision curve analysis, the proposed strategy was associated with higher net benefit. If BS is performed when risk of positive result is >5%, a negative BS is spared in 80% and a positive BS is missed in 2% of the population only.
CONCLUSIONS: Using pre-operative variables, it is possible to accurately estimate the risk of positive BS at RCC staging using pre-operative characteristics. Compared to strategy supported by available guidelines, the proposed model resulted more objective, statistically more accurate and clinically associated with higher net benefit.